Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Clin Invest ; 50(9): e13275, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32406080

RESUMO

BACKGROUND: Both inflammation and oxidative stress may contribute to pathogenesis of metabolic syndrome (MetS). The C242T polymorphism (rs4673) in the CYBA gene, as the main components of NAD (P) H oxidase, causes inter-individual variability in the enzyme activity. We aimed to investigate the association between this polymorphism with MetS and its components. METHODS: Two hundred nine patients with MetS and 232 controls were included in this study. MetS was defined based on NCEP ATP-III A criteria with some modifications. The C242T polymorphism within CYBA gene was determined by using PCR-based restriction fragment length polymorphism (PCR-RFLP) method. RESULTS: After applying a multiple logistic regression model with adjusting for potential confounders of MetS including, age, sex, body mass index, hypertension, used medications, and diabetes mellitus, C242T polymorphism was found to be associated with the presence of MetS in men but not in the total population or in women. T allele as compared to C allele was associated with decreased odds of MetS in men (adjusted OR = 0.42, 95% CI = 0.24-0.74; P = .003), but not in women (adjusted OR = 1.03, 95% CI = 0.07-1.61; P = .890), or in the total population (adjusted OR = 0.72, 95% CI = 0.51-1.02; P = .063). CONCLUSION: This study shows that T allele of C242T polymorphism in CYBA gene is protective against MetS in Iranian men but not in women. Further cohort studies with larger sample size in subgroups of men and women are required to confirm such association in other racial or ethnic group.


Assuntos
Síndrome Metabólica/genética , NADPH Oxidases/genética , Adulto , Idoso , Glicemia/metabolismo , Pressão Sanguínea/genética , Índice de Massa Corporal , Proteína C-Reativa/metabolismo , Estudos de Casos e Controles , HDL-Colesterol/metabolismo , LDL-Colesterol/metabolismo , Dislipidemias/genética , Dislipidemias/metabolismo , Feminino , Predisposição Genética para Doença , Hemoglobinas Glicadas/metabolismo , Humanos , Hipertensão/genética , Modelos Logísticos , Masculino , Síndrome Metabólica/metabolismo , Pessoa de Meia-Idade , Obesidade Abdominal/genética , Razão de Chances , Reação em Cadeia da Polimerase , Polimorfismo Genético , Polimorfismo de Fragmento de Restrição , Fatores Sexuais , Triglicerídeos/metabolismo , Circunferência da Cintura/genética
2.
Artif Cells Nanomed Biotechnol ; 46(2): 293-302, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28362176

RESUMO

Here, we investigated the effects of dual delivery of IGF-1R siRNA and doxorubicin by chitosan nanoparticles on viability of A549 lung cancer cells line by utilization of MTT and qRT-PCR. Furthermore apoptosis and migration of treated cells were assessed by Annexin-PI and wound healing assays, respectively. The chitosan nanoparticles had about 176 nm size with zeta potential and polydispersive index about 11 mV and 0.3, respectively. The IGF-1R siRNA had synergistic effect on DOX-induced cytotoxicity and apoptosis in tumour cells. In addition, siRNA/DOX-loaded chitosan nanoparticles could significantly decrease migration and expressions of mmp9, VEGF and STAT3 in A549 cells.


Assuntos
Quitosana/química , Doxorrubicina/química , Neoplasias Pulmonares/patologia , Nanopartículas/química , RNA Interferente Pequeno/química , Receptor IGF Tipo 1/deficiência , Receptor IGF Tipo 1/genética , Células A549 , Apoptose/efeitos dos fármacos , Apoptose/genética , Movimento Celular/efeitos dos fármacos , Movimento Celular/genética , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/genética , Doxorrubicina/farmacologia , Portadores de Fármacos/química , Liberação Controlada de Fármacos , Humanos , Concentração de Íons de Hidrogênio , Metaloproteinase 9 da Matriz/genética , Invasividade Neoplásica , RNA Interferente Pequeno/genética , Fator de Transcrição STAT3/genética , Fator A de Crescimento do Endotélio Vascular/genética
3.
Avicenna J Med Biotechnol ; 9(1): 8-12, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28090274

RESUMO

BACKGROUND: M2000 is a newly designed and safe Non-Steroidal Anti-Inflammatory Drug (NSAID). The aim of this study was to assess the effects of M2000 on expression levels of Suppressor of Cytokine Signaling-1 (SOCS-1) and Src Homology-2 domain-containing inositol-5'-phosphatase 1 (SHIP1) proteins via Toll-Like Receptor (TLR) 2/microRNA-155 pathway. METHODS: HEK293 TLR2 cell line and Peripheral Blood Mononuclear Cells (PBMCs) were treated by different concentrations of M2000 in MTT assay. RNA was extracted by miRNeasy Mini kit. Then, cDNA was synthesized and the expression levels of SOCS1, SHIP1 and miRNA155 were evaluated by Quantitative Real time PCR. RESULTS: Our results showed that M2000 significantly increased the expression levels of SOCS1 and SHIP-1 in Lipopolysachride (LPS)-treated and non-treated cells. Moreover, M2000 decreased expression level of miR-155 in LPS treated PBMCs. CONCLUSION: M2000 can be used as NSAID in LPS induced inflammation and decrease inflammatory cytokines production by targeting SOCS1, SHIP1 and miR-155 in auto-immune and inflammatory diseases.

4.
Biomed Pharmacother ; 77: 98-107, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26796272

RESUMO

Glioblastoma multiform (GBM) is the most common brain tumor. The current GBM treatments comprise of radiation therapy, chemotherapy and surgery. One of the most important problems regarding the treatment of GBM is the presence of blood brain barrier (BBB) which inhibits the efficient drug delivery into central nervous system (CNS). Nanothechnology can help to deliver therapeutic drugs into CNS through crossing the BBB. There are different types of nanoparticles (Nps) which can be manipulated for clinical applications as a treatment for CNS-related disorders. In this review, we will discuss the role of Nps in the treatment of GBM.


Assuntos
Antineoplásicos/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Glioblastoma/tratamento farmacológico , Nanopartículas/administração & dosagem , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacocinética , Transporte Biológico , Barreira Hematoencefálica/metabolismo , Sistemas de Liberação de Medicamentos , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Humanos , Hipertermia Induzida/métodos , Nanopartículas/química , Nanopartículas/metabolismo , Tamanho da Partícula , Propriedades de Superfície
5.
Curr Stem Cell Res Ther ; 11(1): 41-50, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26329483

RESUMO

Amyotrophic lateral sclerosis (ALS is a neurodegenerative disorder which is characterized by motor neuron (MN dysfunction, progressive paralysis, and death. Although several therapeutic approaches have been used for treatment of ALS, little success has been achieved. Natural vectors such as mesenchymal stem cells (MSCs can be a promising tool for overcoming therapeutic problems. MSCs have multipotential characteristics such as the ability to differentiate into variety of cell types, easy access, immunomodulation, tissue repair, exertion of trophic factors, exosome secretion and efficient homing. In this review, we will discuss the characteristics of MSCs and their possible therapeutic mechanisms in ALS patients.


Assuntos
Esclerose Lateral Amiotrófica/terapia , Transplante de Células-Tronco Mesenquimais/métodos , Animais , Humanos
6.
J Virol Methods ; 193(2): 683-6, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23933079

RESUMO

Hepatitis B virus (HBV) DNA measurement has an important role in the diagnosis and management of patients with chronic HBV infection. In cases of chronic hepatitis B, clinical decision is based on either the absolute amount of HBV DNA level, or else the relative change in HBV DNA level. To produce high quality and comparable results, assay performance characteristics must be verified and statistical quality control methods must be planned. In this study, systematic and random error values in an assay of plasma HBV DNA were determined. Performance of the method was examined by employing a normalized operational process specifications (OPSpecs) chart. The systematic error at low and high control levels were 0.33 and 0.22 log(IU/mL) respectively. At both levels, the standard deviations (SD) of the assay were 0.17 log(IU/mL). In addition, a single rule of 12.5SD with 2 control measurements was selected as a candidate quality control method. The assay performed well and was acceptable for clinical use. Further improvement may be attained by switching to automated purification methods. In this study, the well-established discipline of statistical quality control was applied to a real-time quantitative PCR. It was concluded that by employing statistical quality control (QC) methods, which utilize long-term controls, critical changes in the measurement system could be detected.


Assuntos
DNA Viral/sangue , Vírus da Hepatite B/isolamento & purificação , Hepatite B Crônica/virologia , Controle de Qualidade , Reação em Cadeia da Polimerase em Tempo Real/normas , Carga Viral/normas , Vírus da Hepatite B/genética , Humanos , Plasma/virologia , Reação em Cadeia da Polimerase em Tempo Real/métodos , Carga Viral/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...